000			01564cam a2200229 4500500
005			20250112063006.0
041			_afre
042			_adc
100	1	0	_aFeigerlova, Eva _eauthor
245	0	0	_aVascular events in transgender people
260			_c2023.
500			_a15
520			_aHormonal treatment for transgender people is prescribed to encourage the development of secondary sexual characteristics of the desired gender and to reduce the phenotypic expression of the undesired sex. Data in the literature suggest an increase in cardiovascular morbidity and mortality in this population, but the results are inconclusive because there are no long-term prospective studies that include control subjects. Assessment of cardiovascular health in transgender people and preventive actions should integrate several aspects, such as discrimination-related stress, psychological factors, social stigmatization, lifestyle, and access to care. Current health system priorities include improving access to care for this population and improving the skills of health professionals, as well as implementing clinical and basic research studies.
690			_agender-affirming hormone therapy
690			_atransgender people
690			_avascular function
690			_agender-affirming hormone therapy
690			_atransgender people
690			_avascular function
786	0		_nSang Thrombose Vaisseaux | Volume 35 | 3 | 2023-05-01 | p. 101-108 | 0999-7385
856	4	1	_uhttps://shs.cairn.info/journal-sang-thrombose-vaisseaux-2023-3-page-101?lang=en
999			_c232430 _d232430